Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily L Heil

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|June 23, 2017
Predictors of Adverse Outcomes in Children With Staphylococcus aureus BacteremiaGanesh Kumarachandran, Jennifer Kristie Johnson, Debbie-Ann Shirley, et al.
AIDS Research and Treatment|April 15, 2011
Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected PatientsEmily L Heil, Mary L Townsend, Kenneth Shipp, et al.
Open Forum Infectious Diseases|November 2, 2020
Management of Gram-Negative Bloodstream Infections in the Era of Rapid Diagnostic Testing: Impact With and Without Antibiotic StewardshipKimberly C Claeys, Emily L Heil, Stephanie Hitchcock, et al.
Diagnostic Microbiology and Infectious Disease|August 2, 2021
The potential impact of discrepancies between automated susceptibility platforms and other testing metho`dologies for cefazolin in the treatment of Enterobacterales bloodstream infectionsMandee Noval, Emily L Heil, Paula Williams, et al.
Open Forum Infectious Diseases|June 22, 2026
Recalibration and Validation of a Risk Scoring Tool to Predict Multidrug-Resistant <i>Pseudomonas aeruginosa</i>Nhu Le, Hyunuk Seung, Megan E Dunning, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2025
The Effectiveness of Newer Beta-Lactams for the Treatment of Antimicrobial-Resistant Gram-Negative MeningitisAlice J Hsu, Kathleen Chiotos, Emily L Heil, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 17, 2023
Delabeling for the duration? β-Lactam prescribing in hospitalized patients after penicillin skin testingChristopher M Bland, Emily L Heil, Ashley Asbell, et al.
Open Forum Infectious Diseases|July 25, 2022
Real-world Antimicrobial Stewardship Experience in a Large Academic Medical Center: Using Statistical and Machine Learning Approaches to Identify Intervention "Hotspots" in an Antibiotic Audit and Feedback ProgramKatherine E Goodman, Emily L Heil, Kimberly C Claeys, et al.
Antiviral Therapy|September 8, 2018
Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patientsAna D Vega, Lauren M Hynicka, Kimberly Claeys, et al.
Antimicrobial Agents and Chemotherapy|July 4, 2018
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill PatientsEmily L Heil, David P Nicolau, Andras Farkas, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|June 23, 2017
Predictors of Adverse Outcomes in Children With Staphylococcus aureus BacteremiaGanesh Kumarachandran, Jennifer Kristie Johnson, Debbie-Ann Shirley, et al.
AIDS Research and Treatment|April 15, 2011
Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected PatientsEmily L Heil, Mary L Townsend, Kenneth Shipp, et al.
Open Forum Infectious Diseases|November 2, 2020
Management of Gram-Negative Bloodstream Infections in the Era of Rapid Diagnostic Testing: Impact With and Without Antibiotic StewardshipKimberly C Claeys, Emily L Heil, Stephanie Hitchcock, et al.
Diagnostic Microbiology and Infectious Disease|August 2, 2021
The potential impact of discrepancies between automated susceptibility platforms and other testing metho`dologies for cefazolin in the treatment of Enterobacterales bloodstream infectionsMandee Noval, Emily L Heil, Paula Williams, et al.
Open Forum Infectious Diseases|June 22, 2026
Recalibration and Validation of a Risk Scoring Tool to Predict Multidrug-Resistant <i>Pseudomonas aeruginosa</i>Nhu Le, Hyunuk Seung, Megan E Dunning, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2025
The Effectiveness of Newer Beta-Lactams for the Treatment of Antimicrobial-Resistant Gram-Negative MeningitisAlice J Hsu, Kathleen Chiotos, Emily L Heil, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 17, 2023
Delabeling for the duration? β-Lactam prescribing in hospitalized patients after penicillin skin testingChristopher M Bland, Emily L Heil, Ashley Asbell, et al.
Open Forum Infectious Diseases|July 25, 2022
Real-world Antimicrobial Stewardship Experience in a Large Academic Medical Center: Using Statistical and Machine Learning Approaches to Identify Intervention "Hotspots" in an Antibiotic Audit and Feedback ProgramKatherine E Goodman, Emily L Heil, Kimberly C Claeys, et al.
Antiviral Therapy|September 8, 2018
Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patientsAna D Vega, Lauren M Hynicka, Kimberly Claeys, et al.
Antimicrobial Agents and Chemotherapy|July 4, 2018
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill PatientsEmily L Heil, David P Nicolau, Andras Farkas, et al.
Pageof 12